Patents by Inventor Zahava Vadasz

Zahava Vadasz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODIFIED SEMAPHORIN 3A, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF
    Publication number: 20230272020
    Abstract: Provided herein are modified forms of Semaphorin 3A (Sema3A) polypeptide having one or more amino acid substitutions and/or deletions compared to a wild type Sema3A protein. Further provided are nucleic acid molecules encoding the modified Sema3A polypeptide, compositions including the same and uses thereof in treating various immune-related conditions.
    Type: Application
    Filed: June 3, 2021
    Publication date: August 31, 2023
    Inventors: Zahava VADASZ, Elias TOUBI, Nasren EIZA, Adi SABAG, Gera NEUFELD, Ofra KESSLER, E. Yvonne JONES
  • Semaphorin 3A for treatment and assessment of severity of inflammatory bowel disease
    Patent number: 10736939
    Abstract: Semaphorin 3A and uses thereof for treatment of IBD are provided. Further provided is assessing IBD severity or treatment efficacy, including determining Semaphorin 3A levels in a biological sample of a subject afflicted with IBD.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: August 11, 2020
    Assignee: Medical Research & Development Fund for Health Services Bnai Zion Medical Center
    Inventors: Zahava Vadasz, Elias Toubi
  • Semaphorin 3A for treatment and assessment of severity of Asthma
    Patent number: 10568932
    Abstract: The present invention relates to methods of treating Asthma using Semaphorin 3A. The invention further relates to assessing Asthma severity or treatment efficacy, comprising determining Semaphorin 3A level in a biological sample of a subject afflicted with Asthma.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: February 25, 2020
    Assignee: MEDICAL RESEARCH & DEVELOPMENT FUND FOR HEALTH SERVICES BNAI ZION MEDICAL CENTER
    Inventors: Zahava Vadasz, Elias Toubi
  • PHARMACEUTICAL COMPOSITIONS AND METHODS USEFUL FOR MODULATING ANGIOGENESIS, INHIBITING METASTASIS AND TUMOR FIBROSIS, AND ASSESSING THE MALIGNANCY OF COLON CANCER TUMORS
    Publication number: 20190040470
    Abstract: Methods and compositions suitable for modulating angiogenesis in a mammalian tissue are provided. Further provided are methods suitable for inhibiting metastasis and fibrosis in a mammalian tissue and for assessing the malignancy of colon cancer tumors.
    Type: Application
    Filed: January 26, 2018
    Publication date: February 7, 2019
    Inventors: Gera NEUFELD, Gal AKIRI, Zahava VADASZ, Stela GENGRINOVITCH
  • SEMAPHORIN 3A FOR TREATMENT AND PROGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS
    Publication number: 20190000921
    Abstract: The subject matter relates to Semaphorin 3A (Sema3A) and its use in treatment and prognosis of Systemic Lupus Erythematosus (SLE). Provided are, inter-alia, methods of treating a subject afflicted with SLE, comprising administering to the subject a pharmaceutical composition comprising isolated Sema3A. Further provided are methods for prognosis of SLE, comprising measuring Sema3A serum concentration in a subject in need thereof.
    Type: Application
    Filed: September 14, 2018
    Publication date: January 3, 2019
    Applicant: Medical Research & Development Fund for Health Services Bnai Zion Medical Center
    Inventors: Zahava Vadasz, Elias Toubi
  • Semaphorin 3A as a diagnostic marker for urothelial cancer
    Patent number: 10139412
    Abstract: The present invention is directed to methods and kits useful for diagnosis and/or prognosis of urothelial cancer in a subject. The present invention further relates to methods of assessing severity of cancer and methods of determining efficacy of a treatment for cancer. The methods and kits of the invention comprise determining the levels of semaphorin 3A in a biological sample of a subject.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: November 27, 2018
    Assignees: The Fund for Medical Research, Development of Infrastructure and Health Services—Bnai Zion Medical Center, Technion Research and Development Foundation Limited
    Inventors: Zahava Vadasz, Sarel Halachmi, Jacob Rubinstein, Ofer Nativ, Elias Toubi
  • Semaphorin 3A for treatment of systemic lupus erythematosus
    Patent number: 10105413
    Abstract: The subject matter relates to Semaphorin 3A (Sema3A) and its use in treatment and prognosis of Systemic Lupus Erythematosus (SLE). Provided are, inter-alia, methods of treating a subject afflicted with SLE, comprising administering to the subject a pharmaceutical composition comprising isolated Sema3A. Further provided are methods for prognosis of SLE, comprising measuring Sema3A serum concentration in a subject in need thereof.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: October 23, 2018
    Assignee: Medical Research & Development Fund for Health Services Bnai Zion Medical Center
    Inventors: Zahava Vadasz, Elias Toubi
  • SEMAPHORIN 3A FOR TREATMENT AND ASSESSMENT OF SEVERITY OF INFLAMMATORY BOWEL DISEASE
    Publication number: 20180028604
    Abstract: Semaphorin 3A and uses thereof for treatment of IBD are provided. Further provided is assessing IBD severity or treatment efficacy, including determining Semaphorin 3A levels in a biological sample of a subject afflicted with IBD.
    Type: Application
    Filed: February 9, 2016
    Publication date: February 1, 2018
    Applicant: Medical Research & Development Fund for Health Services Bnai Zion Medical Center
    Inventors: Zahava VADASZ, Elias TOUBI
  • SEMAPHORIN 3A AS A DIAGNOSTIC MARKER FOR UROTHELIAL CANCER
    Publication number: 20160299142
    Abstract: The present invention is directed to methods and kits useful for diagnosis and/or prognosis of urothelial cancer in a subject. The present invention further relates to methods of assessing severity of cancer and methods of determining efficacy of a treatment for cancer. The methods and kits of the invention comprise determining the levels of semaphorin 3A in a biological sample of a subject.
    Type: Application
    Filed: December 2, 2014
    Publication date: October 13, 2016
    Inventors: Zahava VADASZ, Sarel HALACHMI, Jacob RUBINSTEIN, Ofer NATIV, Elias TOUBI
  • SEMAPHORIN 3A FOR TREATMENT AND PROGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS
    Publication number: 20160129079
    Abstract: The subject matter relates to Semaphorin 3A (Sema3A) and its use in treatment and prognosis of Systemic Lupus Erythematosus (SLE). Provided are, inter-alia, methods of treating a subject afflicted with SLE, comprising administering to the subject a pharmaceutical composition comprising isolated Sema3A. Further provided are methods for prognosis of SLE, comprising measuring Sema3A serum concentration in a subject in need thereof.
    Type: Application
    Filed: June 13, 2013
    Publication date: May 12, 2016
    Applicant: Medical Research & Development Fund for Health Ser vices Bnai Zion Medical Center
    Inventors: Zahava VADASZ, Elias TOUBI
  • SEMAPHORIN 3A FOR TREATMENT AND ASSESSMENT OF SEVERITY OF ASTHMA
    Publication number: 20150216929
    Abstract: The present invention relates to methods of treating Asthma using Semaphorin 3A. The invention further relates to assessing Asthma severity or treatment efficacy, comprising determining Semaphorin 3A level in a biological sample of a subject afflicted with Asthma.
    Type: Application
    Filed: February 3, 2015
    Publication date: August 6, 2015
    Inventors: Zahava Vadasz, Elias Toubi
  • PHARMACEUTICAL COMPOSITIONS AND METHODS USEFUL FOR MODULATING ANGIOGENESIS, INHIBITING METASTASIS AND TUMOR FIBROSIS, AND ASSESSING THE MALIGNANCY OF COLON CANCER TUMORS
    Publication number: 20140302499
    Abstract: Methods and compositions suitable for modulating angiogenesis in a mammalian tissue are provided. Further provided are methods suitable for inhibiting metastasis and fibrosis in a mammalian tissue and for assessing the malignancy of colon cancer tumors.
    Type: Application
    Filed: June 20, 2014
    Publication date: October 9, 2014
    Inventors: Gera NEUFELD, Gal AKIRI, Zahava VADASZ, Stela GENGRINOVITCH
  • Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
    Patent number: 8815823
    Abstract: Methods and compositions suitable for modulating angiogenesis in a mammalian tissue are provided. Further provided are methods suitable for inhibiting metastasis and fibrosis in a mammalian tissue and for assessing the malignancy of colon cancer tumors.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: August 26, 2014
    Assignee: Technion Research & Development Foundation Ltd.
    Inventors: Gera Neufeld, Gal Akiri, Zahava Vadasz, Stela Gengrinovitch
  • PHARMACEUTICAL COMPOSITIONS AND METHODS USEFUL FOR MODULATING ANGIOGENESIS, INHIBITING METASTASIS AND TUMOR FIBROSIS, AND ASSESSING THE MALIGNANCY OF COLON CANCER TUMORS
    Publication number: 20120202206
    Abstract: Methods and compositions suitable for modulating angiogenesis in a mammalian tissue are provided. Further provided are methods suitable for inhibiting metastasis and fibrosis in a mammalian tissue and for assessing the malignancy of colon cancer tumors.
    Type: Application
    Filed: March 5, 2012
    Publication date: August 9, 2012
    Applicant: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD.
    Inventors: Gera NEUFELD, Gal Akiri, Zahava Vadasz, Stela Gengrinovitch
  • PHARMACEUTICAL COMPOSITIONS AND METHODS USEFUL FOR MODULATING ANGIOGENESIS, INHIBITING METASTASIS AND TUMOR FIBROSIS, AND ASSESSING THE MALIGNANCY OF COLON CANCER TUMORS
    Publication number: 20120165398
    Abstract: Methods and compositions suitable for modulating angiogenesis in a mammalian tissue are provided. Further provided are methods suitable for inhibiting metastasis and fibrosis in a mammalian tissue and for assessing the malignancy of colon cancer tumors.
    Type: Application
    Filed: March 9, 2012
    Publication date: June 28, 2012
    Applicant: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD.
    Inventors: Gera Neufeld, Gal Akiri, Zahava Vadasz, Stela Gengrinovitch
  • Methods and compositions for modulating angiogenesis
    Patent number: 8168180
    Abstract: Methods and compositions suitable for modulating angiogenesis in a mammalian tissue are provided. Further provided are methods suitable for inhibiting metastasis and fibrosis in a mammalian tissue and for assessing the malignancy of colon cancer tumors.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: May 1, 2012
    Assignee: Technion Research & Development Foundation Ltd.
    Inventors: Gera Neufeld, Gal Akiri, Zahava Vadasz, Stela Gengrinovitch
  • Method for assessing metastatic properties of breast cancer
    Patent number: 8163494
    Abstract: Methods and compositions suitable for modulating angiogenesis in a mammalian tissue are provided. Further provided are methods suitable for inhibiting metastasis and fibrosis in a mammalian tissue and for assessing the malignancy of colon cancer tumors.
    Type: Grant
    Filed: November 27, 2003
    Date of Patent: April 24, 2012
    Assignee: Technion Research & Development Foundation Ltd.
    Inventors: Gera Neufeld, Gal Akiri, Zahava Vadasz, Stela Gengrinovitch
  • PHARMACEUTICAL COMPOSITIONS AND METHODS USEFUL FOR MODULATING ANGIOGENESIS, INHIBITING METASTASIS AND TUMOR FIBROSIS, AND ASSESSING THE MALIGNANCY OF COLON CANCER TUMORS
    Publication number: 20100119515
    Abstract: Methods and compositions suitable for modulating angiogenesis in a mammalian tissue are provided. Further provided are methods suitable for inhibiting metastasis and fibrosis in a mammalian tissue and for assessing the malignancy of colon cancer tumors.
    Type: Application
    Filed: September 30, 2009
    Publication date: May 13, 2010
    Inventors: Gera Neufeld, Gal Akiri, Zahava Vadasz, Stela Gengrinovitch
  • Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
    Publication number: 20060127402
    Abstract: Methods and compositions suitable for modulating angiogenesis in a mammalian tissue are provided. Further provided are methods suitable for inhibiting metastasis and fibrosis in a mammalian tissue and for assessing the malignancy of colon cancer tumors.
    Type: Application
    Filed: November 27, 2003
    Publication date: June 15, 2006
    Applicant: Technion Research & Development Foundation Ltd.
    Inventors: Gera Neufeld, Gal Akiri, Zahava Vadasz, Stela Gengrinovitch
  • Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
    Publication number: 20030114410
    Abstract: Methods and compositions suitable for modulating angiogenesis in a mammalian tissue are provided. Further provided are methods suitable for inhibiting metastasis and fibrosis in a mammalian tissue.
    Type: Application
    Filed: November 27, 2002
    Publication date: June 19, 2003
    Applicant: Technion Research And Development Foundation Ltd.
    Inventors: Gera Neufeld, Gal Akiri, Zahava Vadasz, Stela Gengrinovitch